Skip to content

Moderna

US · MRNA #406 by market cap Listed 2018
195.00 -4.33 -2.17%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Official SEC filings

Source: SEC EDGAR. Latest available cached filings; filing date is not the financial period end. Index checked: 2026-11-22 12:43 UTC.

FormFiledOriginal document
8-K2026-11-16Read on SEC.gov
8-K2026-11-13Read on SEC.gov
10-Q2026-11-06Read on SEC.gov
8-K2026-11-06Read on SEC.gov
8-K2026-09-30Read on SEC.gov
8-K2026-09-01Read on SEC.gov
10-Q2026-07-31Read on SEC.gov
8-K2026-07-31Read on SEC.gov

SEC annual financial snapshot

Standard US-GAAP facts in 10-K filings, USD. Income and cash flow cover the annual period; balance-sheet amounts are as of period end. These are not quarterly or TTM figures. Latest available filed values may include restatements; reporting periods can differ from other providers. Checked: 2026-11-21 11:51 UTC.

MetricUSDBasisPeriod endFiledSource
Revenue$1.94BAnnual2025-12-312026-02-2010-K
Net income$-2.82BAnnual2025-12-312026-02-2010-K
Operating cash flow$-1.87BAnnual2025-12-312026-02-2010-K
Total assets$12.34BAs of2025-12-312026-02-2010-K
Total liabilities$3.69BAs of2025-12-312026-02-2010-K
Stockholders’ equity$8.65BAs of2025-12-312026-02-2010-K
Cash and cash equivalents$2.60BAs of2025-12-312026-02-2010-K

✦ Quant Financial Health how this is computed

Good
  • Altman Z-Score is 13.43, above the 3.0 "safe zone" threshold.
  • Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.

✦ Quant Revenue Concentration how this is computed

Single-engine
  • COVID is the largest reported line at 94.74% of revenue, across 3 reported segments.
  • The next-largest line, Other revenue, is a distant second at 3.05% - a sharp slowdown here would have little to offset it.

Revenue annual, last 8 years

Latest year -39.93% YoY

Margins

Gross margin
54.84%
Operating margin
-159.94%
Net margin
-146.83%

Key ratios & quality

Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.

Income statement

Line item 2018 2019 2020 2021 2022 2023 2024 2025
Revenue 135.07M60.00M803.00M18.47B19.26B6.85B3.24B1.94B
Gross profit 122.51M48.00M266.00M15.12B13.46B2.06B1.74B1.05B
Selling & admin expenses 94.25M110.00M188.00M567.00M1.13B1.55B1.17B1.02B
Research & development 454.08M496.00M1.37B1.99B3.30B4.85B4.54B3.13B
Operating profit -413.27M-546.00M-763.00M13.30B9.42B-4.24B-3.95B-3.07B
Pretax profit -384.41M-515.00M-744.00M13.29B9.58B-3.94B-3.61B-2.77B
Tax 326.00K-1.00M3.00M1.08B1.21B772.00M-46.00M54.00M
Net profit -384.73M-514.00M-747.00M12.20B8.36B-4.71B-3.56B-2.82B
Basic EPS -5-2-23021-12-9-7
Diluted EPS -4.95-1.55-1.9628.2920.12-12.33-9.28-7.26

Balance sheet

Line item 2018 2019 2020 2021 2022 2023 2024 2025
Total current assets 1.56B1.13B6.30B16.07B13.43B10.33B8.10B6.54B
Cash & ST investments 1.52B1.10B4.61B10.73B9.90B8.60B7.03B5.80B
Inventory ----47.00M1.44B949.00M202.00M117.00M153.00M
Total assets 1.96B1.59B7.34B24.67B25.86B18.43B14.14B12.34B
Total current liabilities 222.80M143.12M4.39B9.13B4.92B3.02B2.21B1.99B
Short-term debt ----30.00M211.00M196.00M25.00M37.00M42.00M
Long-term debt --------------590.00M
Total liabilities 431,908,000.00414,612,000.004,776,000,000.0010,524,000,000.006,735,000,000.004,572,000,000.003,241,000,000.003,688,000,000.00
Total equity 1.53B1.17B2.56B14.15B19.12B13.85B10.90B8.65B
Retained earnings -1.01B-1.50B-2.24B9.96B18.32B13.61B10.05B7.22B

Cash flow

Line item 2018 2019 2020 2021 2022 2023 2024 2025
Operating cash flow -330.87M-459.00M2.03B13.62B4.98B-3.12B-3.00B-1.87B
Depreciation & amortization 24.86M31.00M31.00M232.00M348.00M621.00M189.00M215.00M
Free cash flow -436.63M-491.00M1.96B13.34B4.58B-3.83B-4.06B-2.08B
Dividends paid ----------------
Stock buybacks / issuance 563.03M51.00M2.04B-733.00M-3.26B46.00M66.00M35.00M
Ending cash balance 670.49M248.00M2.64B6.86B3.22B2.93B1.93B2.60B

Returns & efficiency

Line item 2018 2019 2020 2021 2022 2023 2024 2025
ROE % -82.11-38.00-39.99146.0850.27-28.59-28.77-28.87
ROA % -26.38-28.95-16.7476.2533.10-21.29-21.87-21.31
ROIC % -82.02-38.03-37.19135.2746.42-28.22-29.59-28.22
5-year avg ROE % --------7.2517.9519.8022.02
EBIT margin % -337.33-1,057.76-267.6375.0150.88-57.80-112.00-143.50
FCF / sales % ----713.8875.1924.27------
Current ratio 7.027.891.431.762.733.423.673.29
Quick ratio 6.977.821.371.542.353.213.453.06
Debt / assets 1.718.333.233.714.646.755.2810.58
LT debt / equity 2.1911.278.084.985.258.796.5114.60
Interest coverage ---76.85-74.31739.06331.17-102.74-149.29-275.80
Revenue CAGR (3Y) % ---22.1015.69425.08632.63191.03-43.50-53.30
Net income CAGR (3Y) % ----------------
FCF CAGR (3Y) % ----------------

Revenue breakdown most recent period

Business

COVID94.74%
Other revenue3.05%
Respiratory syncytial virus (RSV)2.21%

Quote time 2026-11-20 20:02:37 · For reference only, not investment advice and not tailored to your situation.

Moderna discussion 0 comments

Add a comment